You are here
EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease
Phone: (814) 777-8586
Email: yuchaochen@wellsimbiotech.com
Phone: (814) 777-8586
Email: yuchaochen@wellsimbiotech.com
Address:
Type: Domestic Nonprofit Research Organization
PROJECT SUMMARY / ABSTRACT
Alzheimerandapos;s disease (AD) is the most widespread neurodegenerative disorder and has caused a major global
health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental
decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating
studies indicate that neuron-derived extracellular vesicles (EVs) are important biomarkers for AD. However,
researchers face significant challenges in the efficient isolation and accurate analysis of EVs, limiting the broad
study and application of EVs in early diagnosis or targeted therapy of AD. WellSIM proposes to develop and
validate a high-throughput platform and workflow based on our revolutionary EXODUS technique for reliable and
reproducible isolation and analysis of EVs from plasma and CSF with unparalleled throughput, purity, yield, and
sensitivity. Based on hi-EXODUS-NGS and hi-EXODUS-MS integrative analysis, transcriptomic and proteomic
profiling of EVs will be developed to discover and detect EV-derived multi-class biomarkers for AD diagnosis.PROJECT NARRATIVE
One of the significant challenges for clinical validation and application of circulating EVs in AD diagnosis is the
difficulties in efficiently isolating EVs from complicated biofluids with sufficient yield and purity for accurate
interpretation. Our technique could address the unmet needs for EV isolation in AD studies, which will facilitate
early diagnosis and targeted therapy of AD as well as accelerate our understanding of AD pathogenesis and
propagation. Moreover, our study will develop and validate a new methodology and workflow for purification,
profiling, and integrative analysis of EV-derived biomolecules, providing substantial benefits to the EV research
community.
* Information listed above is at the time of submission. *